✓ Translated by DotMD AI Clinical Council Source: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons • Phase III Randomized Trial

Verify Primary Source: NIH PubMed PMID #38387622 ↗

Phase III Randomized Trial: The hepatocyte growth factor mimetic, ANG-3777, in kidney transplant recipients with delayed graft function: Results from a randomized phase 3 trial (N = 248)

Original Paper Title: “The hepatocyte growth factor mimetic, ANG-3777, in kidney transplant recipients with delayed graft function: Results from a randomized phase 3 trial”

Elena Rostova (AI Quant) Rigor Score

88 / 100

Sample Size (Participants)

N = 248

Evidence Classification

Phase III Randomized Trial

Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways

ANG-3777 was well tolerated, and there was a numerically lower incidence of graft failure versus placebo (3.2% vs 8.1%). Although there is insufficient evidence to support an indication of ANG-3777 for patients at risk of renal dysfunction after deceased-donor kidney transplantation, these findings indicate potential biological activity t.
Study Design & Sample: Phase III Randomized Trial published in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (N = 248 human participants).
Biostatistical Rigor Score: 88/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2024), this phase iii randomized trial evaluating 248 human participants investigated: In kidney transplant recipients, delayed graft function increases the risk of graft failure and mortality. Key clinical takeaway: ANG-3777 was well tolerated, and there was a numerically lower incidence of graft failure versus placebo (3.2% vs 8.1%). Although there is insufficient evidence to support an indication of ANG-3777 for patients at risk of renal dysfunction after deceased-donor kidney transplantation, these findings...

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2024-09-15; N = 248; Rigor 88/100): ANG-3777 was well tolerated, and there was a numerically lower incidence of graft failure versus placebo (3.2% vs 8.1%). Although there is insufficient evidence to support an indication of ANG-3777 for patients at risk of renal dysfunction after deceased-donor kidney transplantation, these findings indicate potential biological activity t.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: hgh-human-growth-hormone-2-parts-hypophysis-suis-2-parts-hepar-suis-1 → Condition: kidney-transplantation → Condition: urea-nitrogen-high-uremia-prerenal-azotemia → Condition: acute-nephritic-syndrome-with-minor-glomerular-abnormality →

Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 38387622: Phase III Randomized Trial: The hepatocyte growth factor mimetic, ANG-3777, in kidney transplant recipients with delayed graft function: Results from a randomized phase 3 trial (N = 248)

3 of 3 Free Questions Remaining